Inovio Pharmaceuticals (INO) Stock Is A Strong Play

Inovio Pharmaceuticals INO Stock News

Inovio Pharmaceuticals Inc (NASDAQ: INO) recently made a splash in the market after the company developed a vaccine candidate just 3 hours after receiving the DNA sequence of COVID-19. While Citron worked to downplay the company’s statements, causing pain in the stock, we recently saw somewhat of a recovery after CEPI granted the company $9 million for its work in the space.

Nonetheless, the stock is down yet again today, and pretty big. In fact, it has lost more than 15% this morning as the overall market takes a dive. However, this could be a very big opportunity. Here’s why:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

INO Stock Is Presenting An Opportunity

First and foremost, let’s talk about the dominate discussion across news outlets, the Wuhan coronavirus or COVID-19. So far, there have been more than 174,000 confirmed cases of coronavirus with nearly 7,000 deaths. The virus is rapidly spreading around the world, including in the United States.

In fact, right here at home, schools are shutting down, stores are limiting hours of operation, concerts are being put on hold, conferences are nonexistant and the world is changing as we know it.

With such a serious virus spreading across the world, several companies are working to develop vaccines and treatments. One of these companies is Innovio Pharmaceuticals.

Importantly, the company’s DNA medicines platform allows INO to develop a coronvairus vaccine that’s like nothing else out there, and the company is working quickly to bring it to market. In fact, trials should be starting very soon, and by the end of the year, the company expects to have 1 million doses of the vaccine ready for mass distribution.

Nonetheless, regardless of what happens with COVID-19, this stock could be a very strong play. The company’s work in DNA-based immunotherapies has led to strong signals of efficacy in cervical dysplasia and in the field of oncology.

In fact, INO currently has a Phase 3 trial assessing VGX-3100, a DNA based medication with the potential to generate more than a billion dollars annually if approved. Not to mention, the company’s robust oncology pipeline could prove to be the goose that lays the golden eggs.

Inovio Pharmaceuticals is also in a very good spot financially. The company is losing about $38 million annually. However, cash burn for the year was less than half that. With the money the company has on the books, it can continue to operate for two to three more years. This is plenty of time to bring either a vaccine or one of its investigational treatments to market, opening the door to opportunity.

Final Thoughts

While I view Innovio’s work in the COVID-19 space to be impressive, it’s not the only work that the company is doing. With strong candidates in coronavirus vaccines, oncology and cervical dysplasia, and a strong financial foundation, INO stock has the potential to see dramatic gains ahead!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.